All Trials

MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (any platinum sensitivity; measurable and/or CA-125–evaluable disease; no prior PD‑1/PD‑L1) receive an autologous folate receptor alpha–loaded dendritic cell vaccine plus pembrolizumab. The FRαDC vaccine (monocyte-derived DCs pulsed with multi-epitope FRα peptides to enhance antigen presentation and T‑cell priming against FRα‑overexpressing tumors) is given intradermally alongside standard anti–PD‑1 therapy on a defined 21–42‑day schedule to assess safety and objective response.

ClinicalTrials.gov ID: NCT05920798

Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients With Stage III/IV Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who responded to 3–4 cycles of neoadjuvant carboplatin/paclitaxel and are candidates for interval cytoreductive surgery are randomized to perioperative cisplatin either IV the day before surgery or as intraoperative HIPEC at the end of surgery. Compares safety/tolerability and feasibility of these cisplatin delivery strategies in the perioperative setting.

ClinicalTrials.gov ID: NCT05415709

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and symptomatic malignant ascites/pleural effusion (ECOG 0–1; prior therapies and platinum sensitivity unrestricted) are randomized to pegcetacoplan (C3 complement inhibitor) plus pembrolizumab with or without bevacizumab versus bevacizumab alone. Aims include reducing effusion burden and assessing antitumor activity; key exclusions include active autoimmune disease requiring treatment, recent immunosuppression, recent checkpoint inhibitor, uncontrolled CV disease, and active HBV/HCV viremia.

ClinicalTrials.gov ID: NCT04919629

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent low-grade serous ovarian cancer (measurable disease, ECOG 0–2; up to 5 prior lines; no prior regorafenib or multi-kinase TKIs; limited prior anti-angiogenic therapy) receive regorafenib (oral multikinase inhibitor of VEGFR/PDGFR/FGFR/RAF; ReDOS ramp-up, 3 weeks on/1 week off) plus intramuscular fulvestrant 500 mg (SERD). Aims to assess early objective response and survival/clinical benefit, with safety monitoring and exploratory genomic correlates.

ClinicalTrials.gov ID: NCT05113368

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: HLA-A*02:01–positive adults with unresectable stage III/IV non-ocular melanoma who have progressed after anti–PD-(L)1 (and received anti–CTLA-4; BRAF V600+ must have had BRAF/MEK) are randomized to tebentafusp alone, tebentafusp plus pembrolizumab, or investigator’s choice. Tebentafusp is an ImmTAC TCR–bispecific targeting gp100/HLA-A*02:01 and engaging CD3 to redirect T cells; the study excludes uveal melanoma and patients with active CNS metastases or significant autoimmune disease.

ClinicalTrials.gov ID: NCT05549297

A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant Melanoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable stage III/IV KIT-mutant melanoma (including controlled brain mets), after progression on or ineligible for standard therapy, receive binimetinib (MEK1/2 inhibitor) plus imatinib (KIT/ABL/PDGFR TKI) given continuously in 28‑day cycles. Prior immune checkpoint inhibitors are allowed with washout; key exclusions include significant cardiac/ocular risks and malabsorption.

ClinicalTrials.gov ID: NCT04598009

Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable stage III/IV melanoma that has progressed on prior PD-1/PD-L1 therapy receive lymphodepletion followed by a single infusion of cytokine-induced memory-like NK cells (autologous or haploidentical donor), then nivolumab (PD-1 inhibitor) plus relatlimab (LAG-3 antibody). Allows treated/stable brain metastases; excludes active autoimmune disease requiring immunosuppression, prior severe irAEs leading to permanent ICI discontinuation, TIL therapy, organ allograft, and active viral infections.

ClinicalTrials.gov ID: NCT05629546

A Randomized Phase 2 Trial of Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic melanoma (ECOG 0–1) with at least two measurable lesions and one lesion amenable to hypofractionated radiotherapy are randomized to receive standard ipilimumab (anti–CTLA-4) plus nivolumab (anti–PD-1) with or without HFRT (8 Gy × 3 to a single lesion). Excludes active CNS disease requiring urgent therapy, prior checkpoint inhibitors in the metastatic setting, significant autoimmune disease/immunosuppression, active infections, or HFRT contraindications.

ClinicalTrials.gov ID: NCT03646617

Phase II Study of Binimetinib With Encorafenib in Patients With Metastatic Melanoma and CNS Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with BRAFV600-mutant metastatic melanoma with active CNS involvement (parenchymal and/or leptomeningeal) receive high-dose encorafenib (BRAF inhibitor) plus binimetinib (MEK1/2 inhibitor); includes two cohorts: prior BRAF/MEK–treated with progressive CNS disease and BRAF/MEK–naive, with prior immunotherapy allowed. Aims to evaluate intracranial disease control and PFS with continuous oral therapy; key exclusions include significant cardiovascular disease, recent thromboembolism, and strong CYP3A modulators.

ClinicalTrials.gov ID: NCT05026983

Phase 2 Study of Axitinib + PD-1 Blockade in Mucosal Melanoma With Pilot Addition of Stereotactic Body Radiotherapy or Ipilimumab in Select Progressors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic mucosal melanoma (head/neck including conjunctival, GI, or GU), treatment-naive, ECOG 0–2, including selected patients with brain metastases, receive nivolumab (PD-1 inhibitor) plus axitinib (VEGFR1–3 TKI); at progression, patients may continue doublet with SBRT for oligoprogression or add ipilimumab (CTLA-4 inhibitor) for multifocal/non-SBRT-amenable progression. Primary endpoint is objective response by RECIST 1.1 within 1 year.

ClinicalTrials.gov ID: NCT05384496